Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Review Article

Pathophysiology and Management of Atopic Dermatitis: A Laconic Review

Author(s): Pravin Kumar*, Dinesh Kumar Sharma and Mahendra Singh Ashawat

Volume 15, Issue 4, 2020

Page: [321 - 336] Pages: 16

DOI: 10.2174/1574885514666190828152316

Abstract

Atopic Dermatitis (AD) is long-lasting degenerating skin disease with a characteristic phenotype and stereotypically spread skin lesions. The AD results due to a complex interface among genetic factors, host’s surroundings, pharmacological anomalies and immunological factors. In previous decades, researchers had shown marked interest due to increased prevalence in developed countries. In this review, basics along with the advances in pathogenesis and management of AD have been discussed. The immunological factors i.e. Innate Lymphoid Cells, IL-22 and Toll-like receptors have an important role in the pathogenesis. The proactive topical therapy by skincare, topical glucocorticosteroids and calcineurin inhibitors have improved effect in the management of AD. The human monoclonal antibody-based systemic drug (Duplimab) is a considerable advancement in the management of AD. Other monoclonal antibody-based drugs (Lebrikizumab, Tralokinumab, Apremilast and Nemolizumab) are in different phases of clinical trials. A better understanding of genetics and immunoregulatory cascade will lead to the development of efficacious drugs and better management therapy preventing the relapse of flares and improved life quality of AD patients.

Keywords: Atopic dermatitis, eczema, glucocorticosteroids, skin, duplimab, tacrolimus.

Graphical Abstract
[1]
Kramer ON, Strom MA, Ladizinski B, Lio PA. The history of atopic dermatitis. Clin Dermatol 2017; 35(4): 344-8.
[http://dx.doi.org/10.1016/j.clindermatol.2017.03.005] [PMID: 28709563]
[2]
Leung DYM, Bieber T. Atopic dermatitis. Lancet 2003; 361(9352): 151-60.
[http://dx.doi.org/10.1016/S0140-6736(03)12193-9] [PMID: 12531593]
[3]
Novak N, Bieber T, Leung DYM. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 2003; 112(6): S128-39.
[http://dx.doi.org/10.1016/j.jaci.2003.09.032] [PMID: 14657843]
[4]
Schmid-Grendelmeier P, Simon D, Simon HU, Akdis CA, Wüthrich B. Epidemiology, clinical features, and immunology of the “intrinsic” (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 2001; 56(9): 841-9.
[http://dx.doi.org/10.1034/j.1398-9995.2001.00144.x] [PMID: 11551248]
[5]
Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med 2001; 344(1): 30-7.
[http://dx.doi.org/10.1056/NEJM200101043440106] [PMID: 11136958]
[6]
Björkstén B. Perinatal events in relation to sensitization in the human. Am J Respir Crit Care Med 2000; 162(3 Pt 2): S105-7.
[http://dx.doi.org/10.1164/ajrccm.162.supplement_2.ras-10] [PMID: 10988162]
[7]
Van Bever HP. Early events in atopy. Eur J Pediatr 2002; 161(10): 542-6.
[http://dx.doi.org/10.1007/s00431-002-1028-3] [PMID: 12297901]
[8]
von Mutius E. The environmental predictors of allergic disease. J Allergy Clin Immunol 2000; 105(1 Pt 1): 9-19.
[http://dx.doi.org/10.1016/S0091-6749(00)90171-4] [PMID: 10629447]
[9]
Chan CWH, Law BMH, Liu YH, et al. The association be-tween maternal stress and childhood eczema. Int J Environ Res Public Health 2018; 15(3)E395
[http://dx.doi.org/10.3390/ijerph15030395] [PMID: 29495329]
[10]
Hanifin JM, Rajka G. Diagnostic features of atopic dermati-tis. Acta Derm Venereol Suppl (Stockh) 1980; 92: 44-7.
[11]
Williams HC. Diagnostic criteria for atopic dermatitis: where do we go from here? Arch Dermatol 1999; 135(5): 583-6.
[http://dx.doi.org/10.1001/archderm.135.5.583] [PMID: 10328200]
[12]
Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112(6): S118-27.
[http://dx.doi.org/10.1016/j.jaci.2003.09.033] [PMID: 14657842]
[13]
Schmitt J, Langan S, Williams HC. European Dermato-Epidemiology Network. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol 2007; 120(6): 1389-98.
[http://dx.doi.org/10.1016/j.jaci.2007.08.011] [PMID: 17910890]
[14]
Schmitt J, Langan S, Deckert S, et al. Harmonising outcome measures for atopic dermatitis (HOME) initiative. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol 2013; 132(6): 1337-47.
[http://dx.doi.org/10.1016/j.jaci.2013.07.008] [PMID: 24035157]
[15]
Schmitt J, Spuls P, Boers M, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy 2012; 67(9): 1111-7.
[http://dx.doi.org/10.1111/j.1398-9995.2012.02874.x] [PMID: 22844983]
[16]
Wollenberg A, Barbarot S, Bieber T, et al. European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part I. J Eur Acad Dermatol Venereol 2018; 32(5): 657-82.
[http://dx.doi.org/10.1111/jdv.14891] [PMID: 29676534]
[17]
Severity scoring of atopic dermatitis: The SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 1993; 186(1): 23-31.
[http://dx.doi.org/10.1159/000247298] [PMID: 8435513]
[18]
Ricci G, Dondi A, Patrizi A. Useful tools for the management of atopic dermatitis. Am J Clin Dermatol 2009; 10(5): 287-300.
[http://dx.doi.org/10.2165/11310760-000000000-00000] [PMID: 19658441]
[19]
Steinke JW, Borish L, Rosenwasser LJ. 5. Genetics of hy-persensitivity. J Allergy Clin Immunol 2003; 111(2): S495-501.
[http://dx.doi.org/10.1067/mai.2003.143] [PMID: 12589355]
[20]
Morar N, Willis-Owen SA, Moffatt MF, Cookson WO. The genetics of atopic dermatitis. J Allergy Clin Immunol 2006; 118(1): 24-34.
[http://dx.doi.org/10.1016/j.jaci.2006.03.037] [PMID: 16815134]
[21]
Lee YA, Wahn U, Kehrt R, et al. A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. Nat Genet 2000; 26(4): 470-3.
[http://dx.doi.org/10.1038/82625] [PMID: 11101848]
[22]
Cookson WO, Ubhi B, Lawrence R, et al. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat Genet 2001; 27(4): 372-3.
[http://dx.doi.org/10.1038/86867] [PMID: 11279517]
[23]
Bradley M, Söderhäll C, Luthman H, Wahlgren CF, Kockum I, Nordenskjöld M. Susceptibility loci for atopic dermatitis on chromosomes 3, 13, 15, 17 and 18 in a Swedish population. Hum Mol Genet 2002; 11(13): 1539-48.
[http://dx.doi.org/10.1093/hmg/11.13.1539] [PMID: 12045207]
[24]
Haagerup A, Bjerke T, Schiøtz PO, et al. Atopic dermatitis -- a total genome-scan for susceptibility genes. Acta Derm Venereol 2004; 84(5): 346-52.
[http://dx.doi.org/10.1080/00015550410034426] [PMID: 15370699]
[25]
Zhang Y, Leaves NI, Anderson GG, et al. Positional cloning of a quantitative trait locus on chromosome 13q14 that influences immunoglobulin E levels and asthma. Nat Genet 2003; 34(2): 181-6.
[http://dx.doi.org/10.1038/ng1166] [PMID: 12754510]
[26]
Cookson WO, Sharp PA, Faux JA, Hopkin JM. Linkage between immunoglobulin E responses underlying asthma and rhinitis and chromosome 11q. Lancet 1989; 1(8650): 1292-5.
[http://dx.doi.org/10.1016/S0140-6736(89)92687-1] [PMID: 2566826]
[27]
Young RP, Sharp PA, Lynch JR, et al. Confirmation of genetic linkage between atopic IgE responses and chromosome 11q13. J Med Genet 1992; 29(4): 236-8.
[http://dx.doi.org/10.1136/jmg.29.4.236] [PMID: 1583642]
[28]
Lin S, Cicala C, Scharenberg AM, Kinet JP. The Fc(epsilon)RIbeta subunit functions as an amplifier of Fc(epsilon)RIgamma-mediated cell activation signals. Cell 1996; 85(7): 985-95.
[http://dx.doi.org/10.1016/S0092-8674(00)81300-8] [PMID: 8674126]
[29]
Traherne JA, Hill MR, Hysi P, et al. LD mapping of maternally and non-maternally derived alleles and atopy in FcepsilonRI-beta. Hum Mol Genet 2003; 12(20): 2577-85.
[http://dx.doi.org/10.1093/hmg/ddg290] [PMID: 12944417]
[30]
Forrest S, Dunn K, Elliott K, et al. Identifying genes predisposing to atopic eczema. J Allergy Clin Immunol 1999; 104(5): 1066-70.
[http://dx.doi.org/10.1016/S0091-6749(99)70090-4] [PMID: 10550754]
[31]
Kawashima T, Noguchi E, Arinami T, et al. Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese families. J Med Genet 1998; 35(6): 502-4.
[http://dx.doi.org/10.1136/jmg.35.6.502] [PMID: 9643293]
[32]
Sugiura H, Ebise H, Tazawa T, et al. Large-scale DNA microarray analysis of atopic skin lesions shows overexpression of an epidermal differentiation gene cluster in the alternative pathway and lack of protective gene expression in the cornified envelope. Br J Dermatol 2005; 152(1): 146-9.
[http://dx.doi.org/10.1111/j.1365-2133.2005.06352.x] [PMID: 15656815]
[33]
Egawa G, Weninger W. Pathogenesis of atopic dermatitis: A short review. Cogent Biol 2015; 1: 1-10.
[http://dx.doi.org/10.1080/23312025.2015.1103459]
[34]
Proksch E, Fölster-Holst R, Jensen JM. Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci 2006; 43(3): 159-69.
[http://dx.doi.org/10.1016/j.jdermsci.2006.06.003] [PMID: 16887338]
[35]
Tamari M, Hirota T. Genome-wide association studies of atopic dermatitis. J Dermatol 2014; 41(3): 213-20.
[http://dx.doi.org/10.1111/1346-8138.12321] [PMID: 24628071]
[36]
Rawlings AV, Harding CR. Moisturization and skin barrier function. Dermatol Ther 2004; 17(Suppl. 1): 43-8.
[http://dx.doi.org/10.1111/j.1396-0296.2004.04S1005.x] [PMID: 14728698]
[37]
Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38(4): 441-6.
[http://dx.doi.org/10.1038/ng1767] [PMID: 16550169]
[38]
Smith FJ, Irvine AD, Terron-Kwiatkowski A, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 2006; 38(3): 337-42.
[http://dx.doi.org/10.1038/ng1743] [PMID: 16444271]
[39]
Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 2011; 365(14): 1315-27.
[http://dx.doi.org/10.1056/NEJMra1011040] [PMID: 21991953]
[40]
Lampe MA, Burlingame AL, Whitney J, et al. Human stratum corneum lipids: Characterization and regional variations. J Lipid Res 1983; 24(2): 120-30.
[PMID: 6833889]
[41]
Imokawa G. Ceramides as natural moisturizing factors and their efficacy in dry skin. Cosmetic Science and Technology Series 2002; pp. 267-302.
[42]
Suzuki Y, Nomura J, Koyama J, Horii I. The role of proteases in stratum corneum: involvement in stratum corneum desquamation. Arch Dermatol Res 1994; 286(5): 249-53.
[http://dx.doi.org/10.1007/BF00387596] [PMID: 7520224]
[43]
Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000; 25(2): 141-2.
[http://dx.doi.org/10.1038/75977] [PMID: 10835624]
[44]
Moffatt MF. SPINK5: A gene for atopic dermatitis and asthma. Clin Exp Allergy 2004; 34(3): 325-7.
[http://dx.doi.org/10.1111/j.1365-2222.2004.01915.x] [PMID: 15005722]
[45]
Bieber T. Atopic dermatitis. N Engl J Med 2008; 358(14): 1483-94.
[http://dx.doi.org/10.1056/NEJMra074081] [PMID: 18385500]
[46]
Male D, Roitt I. Introduction to the immune sys-temImmunology. 5th ed. London: Mosby 1998; pp. 1-12.
[47]
Tay SS, Roediger B, Tong PL, Tikoo S, Weninger W. The skin-resident immune network. Curr Dermatol Rep 2013; 3: 13-22.
[http://dx.doi.org/10.1007/s13671-013-0063-9] [PMID: 24587975]
[48]
Weninger W, Biro M, Jain R. Leukocyte migration in the interstitial space of non-lymphoid organs. Nat Rev Immunol 2014; 14(4): 232-46.
[http://dx.doi.org/10.1038/nri3641] [PMID: 24603165]
[49]
Peng W, Novak N. Pathogenesis of atopic dermatitis. Clin Exp Allergy 2015; 45(3): 566-74.
[http://dx.doi.org/10.1111/cea.12495] [PMID: 25610977]
[50]
Grewe M, Bruijnzeel-Koomen CA, Schöpf E, et al. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998; 19(8): 359-61.
[http://dx.doi.org/10.1016/S0167-5699(98)01285-7] [PMID: 9709503]
[51]
Kaesler S, Volz T, Skabytska Y, et al. Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10. J Allergy Clin Immunol 2014; 134(1): 92-9.
[http://dx.doi.org/10.1016/j.jaci.2014.02.017] [PMID: 24698321]
[52]
Hamid Q, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DY. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 1996; 98(1): 225-31.
[http://dx.doi.org/10.1016/S0091-6749(96)70246-4] [PMID: 8765838]
[53]
Wan YY. Multi-tasking of helper T cells. Immunology 2010; 130(2): 166-71.
[http://dx.doi.org/10.1111/j.1365-2567.2010.03289.x] [PMID: 20557575]
[54]
Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 2008; 128(11): 2625-30.
[http://dx.doi.org/10.1038/jid.2008.111] [PMID: 18432274]
[55]
Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 2004; 21(4): 467-76.
[http://dx.doi.org/10.1016/j.immuni.2004.08.018] [PMID: 15485625]
[56]
Shroff A, Guttman-Yassky E. Successful use of ustekinumab therapy in refractory severe atopic dermatitis. JAAD Case Rep 2014; 1(1): 25-6.
[http://dx.doi.org/10.1016/j.jdcr.2014.10.007] [PMID: 27075132]
[57]
Ito Y, Adachi Y, Makino T, et al. Expansion of FOXP3-positive CD4+CD25+ T cells associated with disease activity in atopic dermatitis. Ann Allergy Asthma Immunol 2009; 103(2): 160-5.
[http://dx.doi.org/10.1016/S1081-1206(10)60170-6] [PMID: 19739430]
[58]
Szegedi A, Baráth S, Nagy G, et al. Regulatory T cells in atopic dermatitis: epidermal dendritic cell clusters may contribute to their local expansion. Br J Dermatol 2009; 160(5): 984-93.
[http://dx.doi.org/10.1111/j.1365-2133.2009.09035.x] [PMID: 19222459]
[59]
Samochocki Z, Alifier M, Bodera P, et al. T-regulatory cells in severe atopic dermatitis: Alterations related to cytokines and other lymphocyte subpopulations. Arch Dermatol Res 2012; 304(10): 795-801.
[http://dx.doi.org/10.1007/s00403-012-1290-9] [PMID: 22968402]
[60]
Ou LS, Goleva E, Hall C, Leung DY. T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J Allergy Clin Immunol 2004; 113(4): 756-63.
[http://dx.doi.org/10.1016/j.jaci.2004.01.772] [PMID: 15100684]
[61]
He R, Oyoshi MK, Garibyan L, Kumar L, Ziegler SF, Geha RS. TSLP acts on infiltrating effector T cells to drive allergic skin inflammation. Proc Natl Acad Sci USA 2008; 105(33): 11875-80.
[http://dx.doi.org/10.1073/pnas.0801532105] [PMID: 18711124]
[62]
Nakajima S, Miyachi Y, Kabashima K. Langerhans cells are critical in the pathogenesis of atopic dermatitis via TSLP re-ceptor signaling. J Immunol 2011; 186: 101-3.
[63]
Wollenberg A, Wagner M, Günther S, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002; 119(5): 1096-102.
[http://dx.doi.org/10.1046/j.1523-1747.2002.19515.x] [PMID: 12445198]
[64]
Kim BS, Wang K, Siracusa MC, et al. Basophils promote innate lymphoid cell responses in inflamed skin. J Immunol 2014; 193(7): 3717-25.
[http://dx.doi.org/10.4049/jimmunol.1401307] [PMID: 25156365]
[65]
Monticelli LA, Sonnenberg GF, Artis D. Innate lymphoid cells: critical regulators of allergic inflammation and tissue repair in the lung. Curr Opin Immunol 2012; 24(3): 284-9.
[http://dx.doi.org/10.1016/j.coi.2012.03.012] [PMID: 22521139]
[66]
Roediger B, Kyle R, Yip KH, et al. Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nat Immunol 2013; 14(6): 564-73.
[http://dx.doi.org/10.1038/ni.2584] [PMID: 23603794]
[67]
Kawakami T, Ando T, Kimura M, Wilson BS, Kawakami Y. Mast cells in atopic dermatitis. Curr Opin Immunol 2009; 21(6): 666-78.
[http://dx.doi.org/10.1016/j.coi.2009.09.006] [PMID: 19828304]
[68]
Hershko AY, Suzuki R, Charles N, et al. Mast cell interleukin-2 production contributes to suppression of chronic allergic dermatitis. Immunity 2011; 35(4): 562-71.
[http://dx.doi.org/10.1016/j.immuni.2011.07.013] [PMID: 21982597]
[69]
Hossny E, Aboul-Magd M, Bakr S. Increased plasma eotaxin in atopic dermatitis and acute urticaria in infants and children. Allergy 2001; 56(10): 996-1002.
[http://dx.doi.org/10.1034/j.1398-9995.2001.00169.x] [PMID: 11576081]
[70]
Imai Y, Yasuda K, Sakaguchi Y, et al. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci USA 2013; 110(34): 13921-6.
[http://dx.doi.org/10.1073/pnas.1307321110] [PMID: 23918359]
[71]
Mrabet-Dahbi S, Dalpke AH, Niebuhr M, et al. The Toll-like receptor 2 R753Q mutation modifies cytokine production and Toll-like receptor expression in atopic dermatitis. J Allergy Clin Immunol 2008; 121(4): 1013-9.
[http://dx.doi.org/10.1016/j.jaci.2007.11.029] [PMID: 18234309]
[72]
Niebuhr M, Lutat C, Sigel S, Werfel T. Impaired TLR-2 expression and TLR-2-mediated cytokine secretion in macrophages from patients with atopic dermatitis. Allergy 2009; 64(11): 1580-7.
[http://dx.doi.org/10.1111/j.1398-9995.2009.02050.x] [PMID: 19392987]
[73]
Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347(15): 1151-60.
[http://dx.doi.org/10.1056/NEJMoa021481] [PMID: 12374875]
[74]
Nomura I, Goleva E, Howell MD, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003; 171(6): 3262-9.
[http://dx.doi.org/10.4049/jimmunol.171.6.3262] [PMID: 12960356]
[75]
Howell MD, Gallo RL, Boguniewicz M, et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 2006; 24(3): 341-8.
[http://dx.doi.org/10.1016/j.immuni.2006.02.006] [PMID: 16546102]
[76]
De Benedetto A, Agnihothri R, McGirt LY, Bankova LG, Beck LA. Atopic dermatitis: A disease caused by innate immune defects? J Invest Dermatol 2009; 129(1): 14-30.
[http://dx.doi.org/10.1038/jid.2008.259] [PMID: 19078985]
[77]
Cogen AL, Yamasaki K, Sanchez KM, et al. Selective antimicrobial action is provided by phenol-soluble modulins derived from Staphylococcus epidermidis, a normal resident of the skin. J Invest Dermatol 2010; 130(1): 192-200.
[http://dx.doi.org/10.1038/jid.2009.243] [PMID: 19710683]
[78]
Takai T, Ikeda S. Barrier dysfunction caused by environmental proteases in the pathogenesis of allergic diseases. Allergol Int 2011; 60(1): 25-35.
[http://dx.doi.org/10.2332/allergolint.10-RAI-0273] [PMID: 21173566]
[79]
Kong HH, Oh J, Deming C, et al. NISC Comparative Sequence Program. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 2012; 22(5): 850-9.
[http://dx.doi.org/10.1101/gr.131029.111] [PMID: 22310478]
[80]
Leung DY. Staphylococcus aureus in atopic dermati-tisTextbook of atopic dermatitis. London: Informa Healthcare 2008; pp. 59-68.
[http://dx.doi.org/10.3109/9780203091449.005]
[81]
Baker BS. The role of microorganisms in atopic dermatitis. Clin Exp Immunol 2006; 144(1): 1-9.
[http://dx.doi.org/10.1111/j.1365-2249.2005.02980.x] [PMID: 16542358]
[82]
Kobayashi T, Glatz M, Horiuchi K, et al. Dysbiosis and Staphylococcus aureus colonization drives inflammation in atopic dermatitis. Immunity 2015; 42(4): 756-66.
[http://dx.doi.org/10.1016/j.immuni.2015.03.014] [PMID: 25902485]
[83]
Cork MJ, Danby SG, Vasilopoulos Y, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009; 129(8): 1892-908.
[http://dx.doi.org/10.1038/jid.2009.133] [PMID: 19494826]
[84]
Engler RJ, Kenner J, Leung DY. Smallpox vaccination: Risk considerations for patients with atopic dermatitis. J Allergy Clin Immunol 2002; 110(3): 357-65.
[http://dx.doi.org/10.1067/mai.2002.128052] [PMID: 12209080]
[85]
Cork MJ, Robinson DA, Vasilopoulos Y, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol 2006; 118(1): 3-21.
[http://dx.doi.org/10.1016/j.jaci.2006.04.042] [PMID: 16815133]
[86]
Silverberg JI, Hanifin J, Simpson EL. Climatic factors are associated with childhood eczema prevalence in the United States. J Invest Dermatol 2013; 133(7): 1752-9.
[http://dx.doi.org/10.1038/jid.2013.19] [PMID: 23334343]
[87]
Murray AB, Morrison BJ. It is children with atopic dermatitis who develop asthma more frequently if the mother smokes. J Allergy Clin Immunol 1990; 86(5): 732-9.
[http://dx.doi.org/10.1016/S0091-6749(05)80177-0] [PMID: 2229839]
[88]
Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2007; 120(1): 150-5.
[http://dx.doi.org/10.1016/j.jaci.2007.04.031] [PMID: 17512043]
[89]
Wong SM, Ng TG, Baba R. Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. J Dermatol 2013; 40(11): 874-80.
[http://dx.doi.org/10.1111/1346-8138.12265] [PMID: 24111816]
[90]
Mandeau A, Aries MF, Boé JF, et al. Rhealba® oat plantlet extract: evidence of protein-free content and assessment of regulatory activity on immune inflammatory mediators. Planta Med 2011; 77(9): 900-6.
[http://dx.doi.org/10.1055/s-0030-1250649] [PMID: 21240840]
[91]
Fieten KB, Weststrate AC, van Zuuren EJ, Bruijnzeel-Koomen CA, Pasmans SG. Alpine climate treatment of atopic dermatitis: a systematic review. Allergy 2015; 70(1): 12-25.
[http://dx.doi.org/10.1111/all.12514] [PMID: 25130620]
[92]
Flohr C, Yeo L. Atopic dermatitis and the hygiene hypothesis revisited. Curr Probl Dermatol 2011; 41: 1-34.
[http://dx.doi.org/10.1159/000323290] [PMID: 21576944]
[93]
Pelucchi C, Galeone C, Bach JF, La Vecchia C, Chatenoud L. Pet exposure and risk of atopic dermatitis at the pediatric age: a meta-analysis of birth cohort studies. J Allergy Clin Immunol 2013; 132(3): 616-622.e7.
[http://dx.doi.org/10.1016/j.jaci.2013.04.009] [PMID: 23711545]
[94]
Bath-Hextall F, Delamere FM, Williams HC. Dietary exclusions for improving established atopic eczema in adults and children: systematic review. Allergy 2009; 64(2): 258-64.
[http://dx.doi.org/10.1111/j.1398-9995.2008.01917.x] [PMID: 19178405]
[95]
Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association “Administrative Regulations for Evidence-Based Clinical Practice Guidelines”. J Am Acad Dermatol 2004; 50(3): 391-404.
[http://dx.doi.org/10.1016/j.jaad.2003.08.003] [PMID: 14988682]
[96]
Du Toit G, Roberts G, Sayre PH, et al. LEAP Study Team. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med 2015; 372(9): 803-13.
[http://dx.doi.org/10.1056/NEJMoa1414850] [PMID: 25705822]
[97]
Perkin MR, Logan K, Tseng A, et al. EAT Study Team. Randomized trial of introduction of allergenic foods in breast-fed infants. N Engl J Med 2016; 374(18): 1733-43.
[http://dx.doi.org/10.1056/NEJMoa1514210] [PMID: 26943128]
[98]
Isolauri E, Arvola T, Sütas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000; 30(11): 1604-10.
[http://dx.doi.org/10.1046/j.1365-2222.2000.00943.x] [PMID: 11069570]
[99]
Grüber C. Probiotics and prebiotics in allergy prevention and treatment: future prospects. Expert Rev Clin Immunol 2012; 8(1): 17-9.
[http://dx.doi.org/10.1586/eci.11.74] [PMID: 22149335]
[100]
Wollenberg A, Frank R, Kroth J, Ruzicka T. Proactive therapy of atopic eczema--an evidence-based concept with a behavioral background. J Dtsch Dermatol Ges 2009; 7(2): 117-21.
[http://dx.doi.org/10.1111/j.1610-0387.2008.06772.x] [PMID: 18691346]
[101]
Niedner R. [Therapy with systemic glucocorticoids] Hautarzt 2001; 52(11): 1062-71.
[http://dx.doi.org/10.1007/PL00002604] [PMID: 11757464]
[102]
Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993; 29(3): 501-3.
[http://dx.doi.org/10.1016/S0190-9622(08)82011-7] [PMID: 8349876]
[103]
Barnes L, Kaya G, Rollason V. Topical corticosteroid-induced skin atrophy: a comprehensive review. Drug Saf 2015; 38(5): 493-509.
[http://dx.doi.org/10.1007/s40264-015-0287-7] [PMID: 25862024]
[104]
Hajar T, Leshem YA, Hanifin JM, et al. the National Eczema Association Task Force. A systematic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol 2015; 72(3): 541-549.e2.
[http://dx.doi.org/10.1016/j.jaad.2014.11.024] [PMID: 25592622]
[105]
Haeck IM, Rouwen TJ, Timmer-de Mik L, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. J Am Acad Dermatol 2011; 64(2): 275-81.
[http://dx.doi.org/10.1016/j.jaad.2010.01.035] [PMID: 21122943]
[106]
Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev 2015; 10(10)CD007346
[PMID: 26497573]
[107]
van Velsen SG, De Roos MP, Haeck IM, Sparidans RW, Bruijnzeel-Koomen CA. The potency of clobetasol propionate: serum levels of clobetasol propionate and adrenal function during therapy with 0.05% clobetasol propionate in patients with severe atopic dermatitis. J Dermatolog Treat 2012; 23(1): 16-20.
[http://dx.doi.org/10.3109/09546634.2010.534127] [PMID: 21254880]
[108]
Meurer M, Eichenfield LF, Ho V, Potter PC, Werfel T, Hultsch T. Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a randomized, double-blind trial. J Dermatolog Treat 2010; 21(3): 157-66.
[http://dx.doi.org/10.3109/09546630903410158] [PMID: 20394491]
[109]
Papier A, Strowd LC. Atopic dermatitis: A review of topical nonsteroid therapy. Drugs Context 2018; 7212521
[http://dx.doi.org/10.7573/dic.212521] [PMID: 29632548]
[110]
Kyllönen H, Remitz A, Mandelin JM, Elg P, Reitamo S. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 2004; 150(6): 1174-81.
[http://dx.doi.org/10.1111/j.1365-2133.2004.06017.x] [PMID: 15214906]
[111]
Murrell DF, Calvieri S, Ortonne JP, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol 2007; 157(5): 954-9.
[http://dx.doi.org/10.1111/j.1365-2133.2007.08192.x] [PMID: 17935515]
[112]
Legendre L, Barnetche T, Mazereeuw-Hautier J, Meyer N, Murrell D, Paul C. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. J Am Acad Dermatol 2015; 72(6): 992-1002.
[http://dx.doi.org/10.1016/j.jaad.2015.02.1116] [PMID: 25840730]
[113]
Zane LT, Kircik L, Call R, et al. Crisaborole topical ointment, 2% in patients ages 2 to 17 years with atopic dermatitis: A phase 1b, open-label, maximal-use systemic exposure study. Pediatr Dermatol 2016; 33(4): 380-7.
[http://dx.doi.org/10.1111/pde.12872] [PMID: 27193740]
[114]
Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol 2017; 77(4): 641-649.e5.
[http://dx.doi.org/10.1016/j.jaad.2017.06.010] [PMID: 28823881]
[115]
Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010; 7: 41.
[http://dx.doi.org/10.1186/1476-9255-7-41] [PMID: 20701804]
[116]
Hajar T, Gontijo JRV, Hanifin JM. New and developing therapies for atopic dermatitis. An Bras Dermatol 2018; 93(1): 104-7.
[http://dx.doi.org/10.1590/abd1806-4841.20187682] [PMID: 29641707]
[117]
Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: A phase IIa randomized trial. Br J Dermatol 2016; 175(5): 902-11.
[http://dx.doi.org/10.1111/bjd.14871] [PMID: 27423107]
[118]
Patrizi A, Savoia F, Giacomini F, Tabanelli M, Gurioli C. The effect of summer holidays and sun exposure on atopic dermatitis. G Ital Dermatol Venereol 2009; 144(4): 463-6.
[PMID: 19755951]
[119]
Gambichler T, Kreuter A, Tomi NS, Othlinghaus N, Altmeyer P, Skrygan M. Gene expression of cytokines in atopic eczema before and after ultraviolet A1 phototherapy. Br J Dermatol 2008; 158(5): 1117-20.
[http://dx.doi.org/10.1111/j.1365-2133.2008.08498.x] [PMID: 18363757]
[120]
Dotterud LK, Wilsgaard T, Vorland LH, Falk ES. The effect of UVB radiation on skin microbiota in patients with atopic dermatitis and healthy controls. Int J Circumpolar Health 2008; 67(2-3): 254-60.
[http://dx.doi.org/10.3402/ijch.v67i2-3.18282] [PMID: 18767345]
[121]
Vähävihu K, Ylianttila L, Salmelin R, et al. Heliotherapy improves vitamin D balance and atopic dermatitis. Br J Dermatol 2008; 158(6): 1323-8.
[http://dx.doi.org/10.1111/j.1365-2133.2008.08518.x] [PMID: 18363748]
[122]
Grabbe J, Welker P, Humke S, et al. High-dose ultraviolet A1 (UVA1), but not UVA/UVB therapy, decreases IgE-binding cells in lesional skin of patients with atopic eczema. J Invest Dermatol 1996; 107(3): 419-22.
[http://dx.doi.org/10.1111/1523-1747.ep12363402] [PMID: 8751980]
[123]
Becker D, Langer E, Seemann M, et al. Clinical efficacy of blue light full body irradiation as treatment option for severe atopic dermatitis. PLoS One 2011; 6(6)e20566
[http://dx.doi.org/10.1371/journal.pone.0020566] [PMID: 21687679]
[124]
Mavilia L, Mori M, Rossi R, Campolmi P, Puglisi Guerra A, Lotti T. 308 nm monochromatic excimer light in dermatology: personal experience and review of the literature. G Ital Dermatol Venereol 2008; 143(5): 329-37.
[PMID: 18833074]
[125]
Wollenschläger I, Hermann J, Ockenfels HM. [Targeted UVB-308 nm (NUVB) therapy with excimer laser in the treatment of atopic dermatitis and other inflammatory dermatoses] Hautarzt 2009; 60(11): 898-906.
[http://dx.doi.org/10.1007/s00105-009-1828-8] [PMID: 19711024]
[126]
Syed S, Weibel L, Kennedy H, Harper JI. A pilot study showing pulsed-dye laser treatment improves localized areas of chronic atopic dermatitis. Clin Exp Dermatol 2008; 33(3): 243-8.
[http://dx.doi.org/10.1111/j.1365-2230.2007.02644.x] [PMID: 18201257]
[127]
Kawakami T, Kaminishi K, Soma Y, Kushimoto T, Mizoguchi M. Oral antihistamine therapy influences plasma tryptase levels in adult atopic dermatitis. J Dermatol Sci 2006; 43(2): 127-34.
[http://dx.doi.org/10.1016/j.jdermsci.2006.04.002] [PMID: 16843643]
[128]
Malekzad F, Arbabi M, Mohtasham N, et al. Efficacy of oral naltrexone on pruritus in atopic eczema: A double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol 2009; 23(8): 948-50.
[http://dx.doi.org/10.1111/j.1468-3083.2009.03129.x] [PMID: 19453814]
[129]
Ständer S, Böckenholt B, Schürmeyer-Horst F, et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 2009; 89(1): 45-51.
[http://dx.doi.org/10.2340/00015555-0553] [PMID: 19197541]
[130]
Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991; 338(8760): 137-40.
[http://dx.doi.org/10.1016/0140-6736(91)90134-B] [PMID: 1677063]
[131]
Grundmann-Kollmann M, Podda M, Ochsendorf F, Boehncke WH, Kaufmann R, Zollner TM. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001; 137(7): 870-3.
[PMID: 11453805]
[132]
Simpson EL, Bieber T, Guttman-Yassky E, et al. SOLO 1 and SOLO 2 investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375(24): 2335-48.
[http://dx.doi.org/10.1056/NEJMoa1610020] [PMID: 27690741]
[133]
Hamilton JD, Suárez-Fariñas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 2014; 134(6): 1293-300.
[http://dx.doi.org/10.1016/j.jaci.2014.10.013] [PMID: 25482871]
[134]
Kim BE, Leung DY, Boguniewicz M, Howell MD. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol 2008; 126(3): 332-7.
[http://dx.doi.org/10.1016/j.clim.2007.11.006] [PMID: 18166499]
[135]
Eichenfield L, Flohr C, Simpson E, et al. Lebrikizumab im-proves patient-reported outcomes (PROs) in a phase 2 study in patients with atopic dermatitis. J Am Acad Dermatol 2017; 76: AB423.
[http://dx.doi.org/10.1016/j.jaad.2017.06.133]
[136]
Samrao A, Berry TM, Goreshi R, Simpson EL. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol 2012; 148(8): 890-7.
[http://dx.doi.org/10.1001/archdermatol.2012.812] [PMID: 22508772]
[137]
Abrouk M, Farahnik B, Zhu TH, et al. Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses. J Am Acad Dermatol 2017; 77(1): 177-80.
[http://dx.doi.org/10.1016/j.jaad.2017.03.020] [PMID: 28619562]
[138]
Ruzicka T, Hanifin JM, Furue M, et al. XCIMA study group. anti-interleukin-31 receptor a antibody for atopic dermatitis. N Engl J Med 2017; 376(9): 826-35.
[http://dx.doi.org/10.1056/NEJMoa1606490] [PMID: 28249150]
[139]
Holm JG, Agner T, Sand C, Thomsen SF. Omalizumab for atopic dermatitis: Case series and systematic review of the lit-erature. Int J Dermatol 2016; 1: 1-9.
[PMID: 27337170]
[140]
Godse K, Mehta A, Patil S, Gautam M, Nadkarni N. Omalizumab-a review. Indian J Dermatol 2015; 60(4): 381-4.
[http://dx.doi.org/10.4103/0019-5154.160490] [PMID: 26288408]
[141]
Holm JG, Thomsen SF. Omalizumab for atopic dermatitis: Evidence for and against its use G Ital Deramtol Venereol 2019; 154(4): 480-7.
[http://dx.doi.org/10.23736/S0392-0488.19.06302-8]

© 2022 Bentham Science Publishers | Privacy Policy